Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Poolbeg Pharma Ltd. ( (GB:POLB) ) has issued an announcement.
Poolbeg Pharma plc announced an increase in its BookBuild Offer due to significant oversubscription, raising the number of shares available to 6,000,000, potentially generating gross proceeds of £150,000. The funds will support key clinical trials, including the Phase 2a trial of POLB 001, a potential breakthrough treatment for cancer immunotherapy-induced CRS, and an oral GLP-1 proof of concept trial for obesity treatment. These initiatives could unlock significant market opportunities and attract industry partnerships, enhancing Poolbeg Pharma’s positioning in the biopharmaceutical sector.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. The company’s clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide receptor (GLP-1R) agonist.
Average Trading Volume: 1,046,972
Technical Sentiment Signal: Sell
Find detailed analytics on POLB stock on TipRanks’ Stock Analysis page.